Develops small-molecule drug candidates for people with chronic myeloid leukemia and researches treatments for other diseases.
10-K for FY2025, filed Mar 3, 2026We are a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people…View ↗
ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region –…View ↗
We believe that our development approach, which is rooted in validated biology and differentiated chemistry, enables us to design and…View ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
−$27.7MView ↗
From strategic review to drug development
The older report described the company as having stopped research and development on its previous programs while evaluating strategic options. The latest report describes a clinical-stage small-molecule pipeline led by a candidate for chronic myeloid leukemia, alongside other research programs.
10-K for FY2022, filed Feb 10, 2023 10-K for FY2025, filed Mar 3, 2026We are not currently conducting sales and marketing efforts with respect to any of our previous programs and our plans for future sales and…View ↗
Research and DevelopmentView ↗
We are not currently conducting research and development of any of our previous programs and our plans for future research and development…View ↗
We are a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people…View ↗
ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region –…View ↗
We believe that our development approach, which is rooted in validated biology and differentiated chemistry, enables us to design and…View ↗
Competes with Novartis, Bristol Myers Squibb, Pfizer, Takeda, Ascentage Pharma, Terns Pharmaceuticals, and TargetRx
10-K for FY2025, filed Mar 3, 2026There are currently six BCR-ABL TKIs FDA approved for use in CML: Novartis AG’s Gleevec (imatinib), Tasigna (nilotinib), and Scemblix…View ↗
Loading...